MedPath
HSA Approval

TANSTRIVE HARD CAPSULES 80MG

SIN16991P

TANSTRIVE HARD CAPSULES 80MG

TANSTRIVE HARD CAPSULES 80MG

April 24, 2024

DKSH SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantDKSH SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

ORAL

Medical Information

L01EX22

selpercatinib

Manufacturer Information

DKSH SINGAPORE PTE. LTD.

Lilly del Caribe, Inc.

Lilly, S.A. (Primary and Secondary Packager)

Active Ingredients

Selpercatinib

80.0mg

Selpercatinib

Documents

Package Inserts

Tanstrive Hard Capsule PI.pdf

Approved: April 24, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TANSTRIVE HARD CAPSULES 80MG - HSA Approval | MedPath